Produktbeschreibung
The TY25-CP219 monoclonal antibody is a chimeric version of the original TY25 antibody. The variable domain sequences are identical but the constant region sequences have been switched from rat IgG2a to mouse IgG2c. The mouse IgG2c isotype demonstrates strong effector functions due to potent interaction with mFcgammaRIV, which is functionally similar to the FcgammaRIIIa receptor involved in human ADCC. Mouse strains such as C57Bl/6, C57Bl/10, SJL, and NOD mice possess the Igh1-b allele resulting in only the expression of IgG2c. However, mouse strains such as BALB/c and Swiss Webster mice possess the Igh1-a allele which results in only the expression of IgG2a. It is important to consider matching the Ig-haplotype of the receiving mice to the isotype of the injected antibody to avoid eliciting an undesired immune response. Species-matched chimeric antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The TY25-CP219 monoclonal antibody reacts with mouse PD-L2 (programmed death ligand 2) also known as B7-DC or CD273. PD-L2 is a 25 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L2 is expressed on monocytes, macrophages and subsets of dendritic cells. PD-L2 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L2 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. The TY25 antibody has been reported to block PD-1 mediated interactions in vivo.
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
